Chocolate Touch®
Changing the Landscape of Drug-Coated Balloons

Chocolate platform for controlled inflation
Paclitaxel coating for improved long term results
One step device

Chocolate Touch is the first and only balloon that combines the acute benefits of the Chocolate platform with the sustained long-term effect of paclitaxel.

Pre-Intervention
Inflated Chocolate Touch
Post Chocolate Touch
6 Month Follow-up

ENJERE case from Prof. Thomas Zeller
Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH, Bad Krozingen, Germany.

1 Chocolate BAR interim results.
2 Predictable: less dissection and less bailout stenting.
3 ENDURE interim results.
4 Cadaver data on file at TriReme Medical, LLC.
5 Core lab adjudicated data.
6 Post Chocolate Touch inflation assessments could not be completed in one patient, per protocol, stent was permitted with flow-limiting dissection or >50% stenosis.
7 Based upon Duplex Ultrasound Review by the DUS Corelab (Vascor, Boston MA).
8 Study follow-up and data review is ongoing.
9 Patients treated per protocol.
10 Based upon Angiogram QVA analysis by the QVA Corelab (Yale University, New Haven, CT).
11 At nominal pressure.

See IFU for more information.
The pillows and grooves of the Chocolate® platform were designed to minimize vessel wall trauma. This unique platform has been demonstrated to reduce flow limiting dissections and bail-out stenting. Chocolate Touch is coated with the drug paclitaxel for improved long-term outcomes. It is indicated to treat peripheral vascular disease and does not require pre-dilatation.

**Acute benefits of controlled inflation with the Chocolate platform**

- Predictable luminal gain with unique pillows and grooves design
- Reduced dog-boning and edge injury with uniform inflation
- Demonstrated low rates of dissection and bail out stenting

**ENDURE Procedural Outcomes**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow Limiting Dissections</td>
<td>0% (0/69)</td>
</tr>
<tr>
<td>&gt;50% Diameter Stenosis</td>
<td>1.4% (1/69)</td>
</tr>
<tr>
<td>Bail-out Stenting</td>
<td>1.4% (1/69)</td>
</tr>
</tbody>
</table>

The ENDURE study did not require pre-dilatation.

**ENDURE Results at 6 months**

<table>
<thead>
<tr>
<th>Patency (N=50)</th>
<th>Late Lumen Loss (N=49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>0.16</td>
</tr>
<tr>
<td>Std Dev</td>
<td>±0.72</td>
</tr>
</tbody>
</table>

**Long term benefits of paclitaxel coating**

- Anti-proliferative agent, clinically proven to inhibit neointimal hyperplasia
- 3 µg/mm² paclitaxel dose
- Crystalline paclitaxel coating with hydrophilic excipient, developed in collaboration with InnoRa GmbH

The unique constraining structure of Chocolate Touch covers the drug-coated balloon during delivery and forms pillows upon inflation.

The pillows and grooves of the inflated Chocolate Touch balloon result in 20% more drug-coated surface compared to conventional balloons of the same size.